Zhiwei Chen

No. 2000 Jiangyue Road
Shanghai, 201112, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

A Xerotic Skin-Compatible Neuromotor Electrode Interface for Non-Invasive Muscle Weakness Evaluation in Dermatomyositis.

A Xerotic Skin-Compatible Neuromotor Electrode Interface for Non-Invasive Muscle Weakness Evaluation in Dermatomyositis.

Journal: Advanced materials (Deerfield Beach, Fla.)

Published: January 08, 2026

Upadacitinib Versus Tofacitinib in Anti-MDA5-Positive Dermatomyositis With Interstitial Lung Disease: A Multi-Centre Cohort Study Emulating a Target Trial.

Upadacitinib Versus Tofacitinib in Anti-MDA5-Positive Dermatomyositis With Interstitial Lung Disease: A Multi-Centre Cohort Study Emulating a Target Trial.

Journal: Respirology (Carlton, Vic.)

Published: December 26, 2025

Distinct anti-MDA5 antibody trajectories associated with long-term outcomes in 6-month survivors of anti-MDA5 dermatomyositis with interstitial lung disease.

Distinct anti-MDA5 antibody trajectories associated with long-term outcomes in 6-month survivors of anti-MDA5 dermatomyositis with interstitial lung disease.

Journal: Respiratory research

Published: September 23, 2025

Muscle Visualization and Evaluation Methods for Immune Checkpoint Inhibitor-Related Myositis.

Muscle Visualization and Evaluation Methods for Immune Checkpoint Inhibitor-Related Myositis.

Journal: Journal of visualized experiments : JoVE

Published: September 01, 2025

Efficacy of JAK inhibitor combined with protein A immunoadsorption in MDA5+ dermatomyositis with RPILD: A real-world study.

Efficacy of JAK inhibitor combined with protein A immunoadsorption in MDA5+ dermatomyositis with RPILD: A real-world study.

Journal: Med (New York, N.Y.)

Published: May 12, 2025

Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort study.

Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort study.

Journal: The European respiratory journal

Published: July 28, 2024

Eculizumab Improves Renal Survival in Complement-Mediated TMA Secondary to SLE.

Eculizumab Improves Renal Survival in Complement-Mediated TMA Secondary to SLE.

Journal: Mayo Clinic proceedings

Published: July 10, 2024

Severe gastrointestinal involvements in patients with adult dermatomyositis with anti-NXP2 antibody.

Severe gastrointestinal involvements in patients with adult dermatomyositis with anti-NXP2 antibody.

Journal: RMD open

Published: November 14, 2023

Type I interferon score is associated with the severity and poor prognosis in anti-MDA5 antibody-positive dermatomyositis patients.

Type I interferon score is associated with the severity and poor prognosis in anti-MDA5 antibody-positive dermatomyositis patients.

Journal: Frontiers in immunology

Published: January 26, 2023

Efficacy and safety of tofacitinib in patients with polymyalgia rheumatica: a phase 2 study.

Efficacy and safety of tofacitinib in patients with polymyalgia rheumatica: a phase 2 study.

Journal: Annals of the rheumatic diseases

Published: October 31, 2022

A Computed Tomography Radiomics-Based Prediction Model on Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis.

A Computed Tomography Radiomics-Based Prediction Model on Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis.

Journal: Frontiers in medicine

Published: August 31, 2021

RNA-Containing Immune Complexes Formed by Anti-Melanoma Differentiation Associated Gene 5 Autoantibody Are Potent Inducers of IFN-α.

RNA-Containing Immune Complexes Formed by Anti-Melanoma Differentiation Associated Gene 5 Autoantibody Are Potent Inducers of IFN-α.

Journal: Frontiers in immunology

Published: July 19, 2021

Showing 1-12 of 29

Last Updated: 09/26/2026